CEMI News and Press, Chembio Diagnostics Inc. From 02/24/23

MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administrat...

NEW YORK, NY / ACCESSWIRE / February 6, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Technical Consultants, Inc. ...

NEW YORK, NY / ACCESSWIRE / February 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Albireo Pharma, Inc. (NASDAQ:ALBO)...

A New York-based %Healthcare company already has traders excited on Wednesday morning after it was announced that the company has agreed to be acquired by French firm %Biosynex in an all-cash deal worth $17.2 million, according to the release. This sent shares of ChembioDiagnotics ...

France-based Biosynex has entered into a deal with U.S. company Chembio Diagnostics ( NASDAQ: CEMI ) under which Biosynex will acquire Chembio for $0.45 per share in an all-cash transaction valued at $17.2M. Chembio ( CEMI ) stock soared more than 25% to $0.45 after hours. ...

Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide Synergistic Cost Savings STRASBOURG, France and HAUPPAUGE, N.Y., Jan. 31, 2023 (GLOBE NEWSWIR...

HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) for a Clinical Laboratory Improvement A...

Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Philip Taylor - Investor Relations Rick Eberly - President & Chief Executive Officer Larry Steenvoorden - Executive Vice President & Chief...

Chembio Diagnostics press release ( NASDAQ: CEMI ): Q3 GAAP EPS of -$0.21. Revenue of $11.2M (-7.4% Y/Y). Cash and cash equivalents as of September 30, 2022 totaled $21.1 million, compared to $22.8 million at June 30, 2022. The company received net proceeds of approxim...

HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September ...